Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.

Lipids Tropifexor treatment was associated with an overall trend of increase in low-density lipoprotein cholesterol (LDL-C) and decrease in high-density lipoprotein cholesterol (HDL-C) levels (Extended Data Fig. 2 ); however, few patients were initiated on lipid-lowering drugs during the study (placebo, n = 1; tropifexor 140 μg, n = 0; tropifexor 200 μg, n = 2) and changes in LDL-C and HDL-C levels in the tropifexor groups stabilized after week 12.

also in 4,871 other papers